华兰疫苗：重组带状疱疹疫苗获得药物临床试验批准通知书

Core Viewpoint - Hualan Vaccine has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine (CHO cells), marking a significant step in the development of a vaccine aimed at preventing herpes zoster [1][3]. Group 1: Company Developments - The recombinant herpes zoster vaccine (CHO cells) is designed to induce immune responses to reduce the risk of herpes zoster and its related complications [3]. - The approval for clinical trials allows Hualan Vaccine to officially enter the clinical testing phase, which will further validate the product's safety and efficacy, laying the groundwork for future registration and market launch [3]. - This approval enriches the company's pipeline of vaccine products under development, which is expected to have a positive impact on the company's future growth [3]. Group 2: Industry Context - Herpes zoster is caused by the reactivation of the varicella-zoster virus and primarily affects adults and the elderly with weakened immune systems, leading to significant pain and reduced quality of life [2]. - The prevalence of herpes zoster in China is approximately 6.15%, with rates increasing significantly with age, reaching 12.95% in individuals aged 70 and above [2]. - Vaccination is recognized as an important preventive measure that can significantly reduce the risk of herpes zoster and its complications, indicating a growing demand for herpes zoster vaccines in the context of an aging population and increasing public health awareness [2].